Tag: FSD Pharma Inc.

FSD Pharma Announces Holdings in Cannara Biotech Inc.

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma (“FSD“) announced today that, in connection with the business combination (the “Business Combination“) completed on December 31, 2018 among Cannara Biotech Inc. (formerly, Dunbar Capital Corp.) (the “Issuer“), Cannara Biotech Inc. and 11038427 Canada Inc., FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares (“Common Shares“) of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer. read more

FSD Pharma Completes Harvest and Passes Analytical Testing of Second Lot

Company in position for pre-sales license inspection, last step to issuance
MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) is pleased to announce that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), a licensed cannabis producer under the Cannabis Act, has completed the harvest of its second lot of cannabis and successfully passed all analytical testing, thereby positioning the Company to request a Pre-Sales License Inspection from Health Canada. The Pre-Sales License Inspection is the last step prior to the issuance of a Sales License under the Cannabis Act and Regulations. read more

FSD Pharma Responds to Therapix Termination of Binding LOI

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) in response to Therapix Biosciences’ termination of the company’s binding letter of intent (LOI) to be acquired by FSD Pharma, Dr. Raza Bokhari, Executive Co-Chairman of the Board of FSD Pharma, released the following statement: read more

FSD Pharma Announces Strategic Investment in Huge Shops

– Huge Shops forms alliance with Coffee Time’s parent company Chairman’s Brands to establish retail distribution network –
MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) has completed a strategic investment of $1.3 million or just under 9.9% in Huge Shops, a Toronto-based cannabis retailer. Huge Shops has a strategic alliance with Chairman’s Brands, parent company of Coffee Time, a well-established operator of retail coffee shops with more than 75 locations in Canada and other locations worldwide. read more

FSD Pharma Congratulates High Tide for Its Listing and Commencement of Trading on the CSE

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) would like to congratulate High Tide Inc. (“High Tide”) for its listing approval and commencement of trading on the Canadian Securities Exchange (“CSE”) today under the stock symbol “HITI”.  FSD has been a founding shareholder of High Tide since participating in its non-brokered private placement that closed on May 2, 2018, while adding to its position by participating in High Tide’s offering of special warrants that closed on October 2, 2018. read more

FSD Pharma Featured in CannaInvestor Magazine December Issue

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) today announced that it is the featured company in the CannaInvestor Magazine December 2018 Issue. CannaInvestor Magazine is the leading industry investment magazine for cannabis investors, analysts, executives, entrepreneurs, and the financial media. The digital version of the magazine is accessible and free to all subscribers who enter their email address. FSD Pharma’s cover feature can be found by clicking on this link https://joom.ag/0j5a or visiting CannaInvestor Magazine’s website www.cannainvestormag.ca. read more

FSD Pharma Announces Collaboration and License Agreement with World Class Extractions

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9), which, through its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), is a licensed producer pursuant to the Cannabis Act, announced today that it has entered into a definitive Collaboration and License Agreement (the “Agreement”) with World Class Extractions Inc. (“World Class”), a company that has developed a unique extraction process designed to produce quality, potent cannabis extracts. World Class is also in the process of completing its own previously announced reverse takeover of CBD Med Research Corp. (the “RTO”), and submitted its initial listing application to the Canadian Securities Exchange (the “CSE”) late last week. read more

FSD Pharma congratulates partner Canntab on launch of research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D.

– FSD Pharma to work with Canntab to create tablets for the clinical research study at its facility in Cobourg, Ontario, Canada –
MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) today congratulated strategic partner Canntab Therapeutics Limited (“Canntab”) on the launch of a research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D. Dr. Garbuz will be the lead investigator on a clinical research study at the University of British Columbia subject to the University’s approval that aims to show the potential for reduction or elimination of the use of opiates in orthopaedic patients using Canntab’s sustained release tablets. Canntab will create the tablets for the study in Cobourg, Ontario with FSD Pharma in furtherance of their collaboration and license agreement dated September 17, 2018. read more

Canntab Enters Into a Binding Term Sheet With Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D. for a Clinical Research Trial of Canntab’s Tablets

MotherlodeTV
canntab, c.pill, cannabis
  • Partnership formed with Dr. Don Garbuz, an award winning orthopaedic surgeon and medical researcher, credited with over 120 peer reviewed publications.
  • The parties will seek to conduct a clinical study with orthopaedic patients, using Canntab’s sustained release tablets.
  • The study aims to show the potential for reduction or elimination of the use of opiates in patients, a major epidemic throughout North America.
  • The study will also seek to show the efficacy of Canntab’s cannabis products for pain management and improvements in patient overall health outcomes.

Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”), today announces the launch of a research partnership with world-renowned orthopaedic surgeon, Dr. Don Garbuz, M.D. (Head of the Division of Lower Limb Reconstruction and Oncology of the Department of Orthopaedics at the University of British Columbia), subject to approval of the University of British Columbia where the proposed clinical trial will take place. The aim of the study is to examine and quantify the efficacy of Canntab products in decreasing the duration and quantity of postoperative use of opioid medications and in the management of preoperative pain. Dr. Garbuz shall be the Lead Investigator for the research study. read more

FSD Pharma Achieves Over 4 Billion Shares Traded in First 6 Months

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that the Company has traded over four Billion Class B subordinate voting shares in its first six months of trading on the Canadian Securities Exchange (“CSE”). During the period of May 29, 2018 to November 29, 2018, the Company traded exactly 4,041,346,300 Class B subordinate voting shares on the CSE. This is the largest total quantity of share volume ever traded by a CSE listed issuer within one year of consecutive days of trading as confirmed by the CSE. read more